7β, 10β-Dimethoxydocetaxel 183133-96-2 Cabazitaxel
NLT 99.5% HPLC
COA,NMR,HPLC,MSDS, ROS, DMF all available.
We are offering three key services for new drug application,
a. Mature(repeatable) pilot process with independent intellectual property rights;
b. High purity sample designed for pharm companies;
c. Impurity study.
From Wikipedia, the free encyclopedia,
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View